TRACON Pharma (NASDAQ: TCON)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.420 | -0.480 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of TRACON Pharma (NASDAQ: TCON) through any online brokerage.
Other companies in TRACON Pharma’s space includes: Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD), Larimar Therapeutics (NASDAQ:LRMR) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for TRACON Pharma (NASDAQ: TCON) was reported by Baird on Wednesday, February 23, 2022. The analyst firm set a price target for 10.00 expecting TCON to rise to within 12 months (a possible 395.05% upside). 1 analyst firms have reported ratings in the last year.
The stock price for TRACON Pharma (NASDAQ: TCON) is $2.02 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for TRACON Pharma.
TRACON Pharma’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for TRACON Pharma.
TRACON Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.